Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment of $250M and up to an additional $752.5M in ...

The Bedford company announced its acquisition of Evergreen Theragnostics Inc. Tuesday. Lantheus (Nasdaq: LNTH) is paying $250 million upfront in the all-cash transaction, plus up to an additional ...

Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen Theragnostics for $250 million upfront. As part of the deal, which was announced ...

Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment of $250M and up to an additional $752.5M in ...

Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.

(RTTNews) - Lantheus Holdings (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics, Inc. in an all-cash transaction consisting of an upfront payment of $250 million and up to ...

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics.

Lantheus Holdings (NasdaqGM:LNTH) saw an 18.83% increase in its share price over the past week, driven by recent corporate updates and market trends. The company announced its 2024 earnings, reporting ...

Brian Markison, CEO Evergreen Theragnostics is expected to add Octevy, a registrational stage PET radiodiagnostic that would complement Lantheus' therapeutic candidate, PNT2003. Both acquisitions ...